We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-6.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$647M
AUM Growth
-$83.7M
Cap. Flow
-$10M
Cap. Flow %
-1.55%
Top 10 Hldgs %
49.16%
Holding
110
New
21
Increased
23
Reduced
14
Closed
30

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$30.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$24M
3
NVO
Novo Nordisk
NVO
+$22.8M
4
PTCT icon
PTC Therapeutics
PTCT
+$13.5M
5
GILD icon
Gilead Sciences
GILD
+$13.4M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$31.8M
2
GSK icon
GSK
GSK
+$20M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$19.3M
4
VRNT
Verint Systems
VRNT
+$15.6M
5
BLUE
bluebird bio
BLUE
+$9.54M

Sector Composition

Rank Sector Weight
1 Healthcare 74.15%
2 Technology 11.83%
3 Industrials 2.25%
4 Consumer Discretionary 1.19%
5 Communication Services 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLT icon
101
iShares 20+ Year Treasury Bond ETF
TLT
$42.1B
– –
-45,000
Closed -$5.98M
VTGN icon
102
VistaGen Therapeutics
VTGN
$9.89M
– –
-22,454
Closed -$489K
VTRS icon
103
Viatris
VTRS
$20.4B
– –
-400,000
Closed -$7.62M
WVE icon
104
Wave Life Sciences
WVE
$1.09B
– –
-307,967
Closed -$8.04M
XHB icon
105
State Street SPDR S&P Homebuilders ETF
XHB
$1.6B
– –
-166,796
Closed -$6.95M
ITCI
106
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-300,000
Closed -$3.89M
MRNS
107
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-20,000
Closed -$332K
ORTX
108
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-10,743
Closed -$1.5M
ICPT
109
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-116,000
Closed -$9.23M
MYOK
110
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-140,000
Closed -$7.02M
1 2 3 4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2019 Portfolio in Review

As of Q3 2019, Sphera Funds Management held 110 positions worth $647M, down 11% from $731M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sphera Funds Management's Q3 2019 filing shows 21 new, 23 increased, 14 reduced and 30 closed positions. Its largest new stake was Sanofi: 700,000 shares worth $32.4M. The largest sale was AstraZeneca, an estimated $31.8M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 70% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q3 2019 buy was Sanofi: 700,000 shares worth $32.4M.
  • Sphera Funds Management added most to Sarepta Therapeutics in Q3 2019, an estimated $24M increase.
  • Sphera Funds Management's biggest Q3 2019 reduction was Alexion Pharmaceuticals, cutting an estimated $19.3M.
  • Sphera Funds Management fully exited AstraZeneca in Q3 2019, selling an estimated $31.8M.
  • Sphera Funds Management's ten largest holdings make up 49% of its $647M portfolio in Q3 2019.
  • Sphera Funds Management opened 21 new positions and closed 30 in Q3 2019.
  • Sphera Funds Management's portfolio value fell 11% quarter-over-quarter to $647M.

Based on Sphera Funds Management's 13F filing for Q3 2019, filed 14 Nov 2019.